CYP1A1 allele frequency in AML patients (all cases and subgroups) with or without FLT3 internal tandem duplication
| . | CYP1A1allele frequency . | |||
|---|---|---|---|---|
| FLT3 ITDs no. (%) . | ITDs no. (%) . | OR . | 95% CI . | |
| All cases* | ||||
| Ile/Ile | 67 (93) | 326 (92) | 0.84 | 0.31-2.25 |
| Ile/Val or Val/Val | 5 (7) | 29 (8) | ||
| Good-risk karyotypes t(15;17), t(8;21), inv(16) | ||||
| Ile/Ile | 48 (94) | 154 (91) | 0.64 | 0.18-2.31 |
| Ile/Val or Val/Val | 3 (6) | 15 (9) | ||
| Intermediate karyotypes | ||||
| Ile/Ile | 14 (100) | 77 (94) | 0.49 | 0.02-9.3 |
| Ile/Val or Val/Val | 0 (0) | 5 (6) | ||
| Poor-risk karyotypes 5q/7q or 3q | ||||
| Ile/Ile | 5 (71) | 95 (91) | 4.22 | 0.71-25.0 |
| Ile/Val orVal/Val | 2 (19) | 9 (9) | ||
| . | CYP1A1allele frequency . | |||
|---|---|---|---|---|
| FLT3 ITDs no. (%) . | ITDs no. (%) . | OR . | 95% CI . | |
| All cases* | ||||
| Ile/Ile | 67 (93) | 326 (92) | 0.84 | 0.31-2.25 |
| Ile/Val or Val/Val | 5 (7) | 29 (8) | ||
| Good-risk karyotypes t(15;17), t(8;21), inv(16) | ||||
| Ile/Ile | 48 (94) | 154 (91) | 0.64 | 0.18-2.31 |
| Ile/Val or Val/Val | 3 (6) | 15 (9) | ||
| Intermediate karyotypes | ||||
| Ile/Ile | 14 (100) | 77 (94) | 0.49 | 0.02-9.3 |
| Ile/Val or Val/Val | 0 (0) | 5 (6) | ||
| Poor-risk karyotypes 5q/7q or 3q | ||||
| Ile/Ile | 5 (71) | 95 (91) | 4.22 | 0.71-25.0 |
| Ile/Val orVal/Val | 2 (19) | 9 (9) | ||
Ile/Ile, homozygous for Ile allele common among whites. Ile/Val or Val/Val,heterozygous or homozygous, respectively, for the*2B Val allele. CI indicates confidence interval.
n = 427.